Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Voorraadrapport

Marktkapitalisatie: CN¥3.5b

Cabio Biotech (Wuhan) Beheer

Beheer criteriumcontroles 3/4

De CEO Cabio Biotech (Wuhan) is Dewei Yi, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. bezit rechtstreeks 1.39% van de aandelen van het bedrijf, ter waarde CN¥ 48.35M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 5.9 jaar.

Belangrijke informatie

Dewei Yi

Algemeen directeur

CN¥1.1m

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO8.9yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn8.9yrs
Gemiddelde ambtstermijn bestuur5.9yrs

Recente managementupdates

Recent updates

We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Nov 04
We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Oct 28
Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

CEO

Dewei Yi (59 yo)

8.9yrs

Tenure

CN¥1,090,600

Compensatie

Mr. Dewei Yi is Chairman and General Manager of CABIO Biotech(Wuhan) Co., Ltd., since December 2015. From December 1999 he has been the chairman of Wuhan Xiwang Biological Engineering Co., Ltd.; since Nove...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dewei Yi
Chairman & GM8.9yrsCN¥1.09m1.39%
CN¥ 48.4m
Huabiao Wang
Financial Director & Director8.9yrsCN¥781.40k0.66%
CN¥ 23.0m
Huarong Yi
Deputy GM & Secretary of the Board of Directorsno dataCN¥640.10k0.089%
CN¥ 3.1m
Anfeng Geng
Deputy General Manager3.7yrsCN¥713.40k0.098%
CN¥ 3.4m
Zhiming Wang
Deputy General Manager2.9yrsCN¥862.90k0.14%
CN¥ 5.0m
Xiangyu Li
Deputy General Manager8.9yrsCN¥763.90k0.12%
CN¥ 4.2m
Tao Ma
Deputy General Manager8.9yrsCN¥640.90k0.093%
CN¥ 3.3m
Hao Xiong
Accounting Supervisorno datageen gegevensgeen gegevens

8.9yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 688089 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Dewei Yi
Chairman & GM8.9yrsCN¥1.09m1.39%
CN¥ 48.4m
Huabiao Wang
Financial Director & Director8.9yrsCN¥781.40k0.66%
CN¥ 23.0m
Bin Du
Vice Chairman8.9yrsCN¥984.80k0.58%
CN¥ 20.3m
Yujun Wu
Employee Representative Supervisor8.9yrsgeen gegevens0.018%
CN¥ 634.3k
Chunyu Zhang
Director2.9yrsgeen gegevensgeen gegevens
Xiangdong Chen
Independent Director2.9yrsCN¥80.00kgeen gegevens
Qi Liu
Independent Director2.9yrsCN¥80.00kgeen gegevens
Jing Chen
Supervisor2.9yrsgeen gegevensgeen gegevens

5.9yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688089 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).